Navigation Links
PharmAthene Reports Third Quarter 2011 Financial and Operating Results
Date:11/9/2011

facturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, challenges related to the implementation of our NYSE Amex compliance plan as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC"). In particular, there is significant uncertainty regarding the level and timing of sales of ST-246 and when and whether it will be approved by the U.S. FDA and corresponding health agencies around the world. We cannot predict with certainty when SIGA will commence delivering any product or will begin recognizing profit on the sale thereof and there can be no assurance that any profits received by SIGA and paid to us will be significant. Furthermore, the Court of Chancery may grant SIGA's motion for reargument and the Court of Chancery decision could be appealed by SIGA, and there can be no assurances that the decision will not be reversed or that the remedy will not otherwise be modified. In addition, to the extent that there is an appeal, we cannot predict how long that will delay the receipt of payments, if any, from SIGA. Further, significant additional non-clinical animal studies, human clinical trials, and manufacturing development work remain to be completed for SparVax ™, Valortim® and our rBChE product. Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at www.PharmAthene.com. -- Tables Follow --PHARMATHENE, INC.CONDENSED CONSOLIDATED BALANCE SHEETSSeptember 30,December 31,2011Unaudited2010ASSETSCurrent assets:Cash and cash equivalents$

10,406,076$

11,785,327Restricted cash100,000100,000Accounts receivable, net4,039,7015,367,130Other re
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
2. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
3. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
4. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
5. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
6. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
7. PharmAthene Completes $6.5 Million Registered Direct Offering
8. PharmAthene Reports First Quarter 2011 Financial and Operating Results
9. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
10. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
11. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... November 21, 2014 Why did Stephen ... Albert Einstein so instantly recognizable? Why have they become ... astronomer and author Hilton Ratcliffe seeks out the answers ... at all to do with science. In " Stephen ... , November 21, 2014), Ratcliffe puts it plainly: ...
(Date:11/21/2014)... Dallas, Texas (PRWEB) November 21, 2014 ... Industry” is a professional and in-depth research report ... information, including its definition, classification, application, and industry ... research covers the international market analysis, including China’s ... covering macroeconomic environment & economic situation analysis. The ...
(Date:11/21/2014)... 20, 2014 /CNW/ - Aequus Pharmaceuticals Inc. (the ... it has closed a brokered private placement offering ... C$3.7 million.  Cormark Securities Inc. and Clarus Securities ... Offering for a syndicate of agents that also ... (collectively the "Agents"). Concurrently with the Brokered Offering, ...
(Date:11/21/2014)... 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... September 30, 2014.  Biorem,s complete 2014 third quarter financial statements and ... Financial Summary:Three-months ended September 30, , Nine-months ended ... , 2014 , 2013 , 2014 ... 5,281 , 6,715 , 14,476 Gross profit ...
Breaking Biology Technology:“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 2International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 3Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3
... Nabriva Therapeutics, a,specialist in antibiotics development, announces that ... Officer of the Company., Dr. Golumbeski brings ... serving most recently as Vice President of Business ... at Novartis. In this,position he was responsible for ...
... HAIKOU CITY, China, July 2 /Xinhua-PRNewswire-FirstCall/,-- China Pharma ... develops, manufactures, and markets generic and branded bio-,pharmaceutical ... will,present at the Collins Stewart Fourth Annual Growth ... The conference is being held at the Mandarin,Oriental ...
... develops new therapies based on cells manufactured from ... A/S provide funding round, SALT LAKE CITY and ... at the forefront of innovative cell therapies,for the treatment ... a,$14.5MM Series A financing. The round was led by ...
Cached Biology Technology:Nabriva Therapeutics Announces Appointment of New CEO 2China Pharma Holdings, Inc. to Present at Collins Stewart Fourth Annual Growth Conference in New York on July 8, 2008 at 2:00 p.m. EDT 2AlloCure Inc. Closes $14.5MM Series A Round to Develop a Stem Cell Therapy for Acute Kidney Injury 2AlloCure Inc. Closes $14.5MM Series A Round to Develop a Stem Cell Therapy for Acute Kidney Injury 3
(Date:11/12/2014)... GARDENS, Fla. , Nov. 12, 2014 ... announced today that its U.are.U ® fingerprint readers ... bakery chain in Central Mexico . ... June 2014 to eliminate payroll issues caused by employees ... to installing the U.are.U fingerprint readers, Montparnasse relied on ...
(Date:11/7/2014)... Leading Biometric companies aim to provide ... online transactions.  Companies in focus today are: NXT-ID, Inc. (NASDAQ: ... BABA ), Google Inc. (NASDAQ: GOOG ), Microsoft ... EBAY ) and MasterCard Inc. (NYSE: MA) ... biometric authentication company focused on the growing mobile commerce is ...
(Date:11/5/2014)... biology in the UTSA College of Sciences, is ... to receive a two-year $300,00 National Science Foundation ... The funding supports President Obama,s BRAIN Initiative, a ... technology that will demystify complex brain processes. ... are broken into the interactions of multiple components, ...
Breaking Biology News(10 mins):Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3
... that certain proteins, known as transcription factors, directly control ... As a result, it is widely believed that ... responsible for evolutionary adaptation. The idea that small ... in evolutionary changes to animals, appearance is completely new. ...
... A new report on the potential effects of climate ... existing observations and science-based expectations to identify how climate ... sanctuary and adjacent coastal areas. It also ... officials called it the first step toward addressing them. ...
... a complex region of the human genome has helped 14 ... new territory in immunity research. , They have discovered that ... operate and, potentially, what they fight off, actually vary from ... vaccinations are designed to treat whole populations our response to ...
Cached Biology News:A surprising new function for small RNAs in evolution 2Olympic Coast Sanctuary report is 'first step' in addressing effects of climate change 2Scientists find ethnicity linked to antibodies 2
...
...
... Performance, 5 ml. The same high ... Streptavidin columns for fast, reliable purification ... Tricorn 5/50 GL, XK 16/20, or ... are required.Extremely useful for exploiting either ...
Luminometers...
Biology Products: